Molecular Theranostics
Ohio, US · 1 known investors
MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.
Founders & leadership
AC
Audrey Carballo
Investors · 1
Competitors · 2
by search overlapUclahealth3 shared keywordsUCLA Health is an academic health system providing primary, immediate, and specialty medical care including cancer, neuroscience, transplant, orthopedics, cardiovascular, and children's care. It operates hospitals and clinics and trains medical students, with a network of locations in the Los Angeles area.
Mtem3 shared keywordsMolecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX. The company is no longer operating.
Companies competing with Molecular Theranostics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $265.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $249.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Molecular Theranostics do?
- MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.
- Who are Molecular Theranostics's investors?
- Molecular Theranostics's investors include CWRU Technology Ventures.
- Where is Molecular Theranostics headquartered?
- Molecular Theranostics is headquartered in Ohio, US.